Francica Alessandra, Tonelli Filippo, Rossetti Cecilia, Tropea Ilaria, Luciani Giovanni Battista, Faggian Giuseppe, Dobson Geoffrey Phillip, Onorati Francesco
Division of Cardiac Surgery, University of Verona Medical School, 37126 Verona, Italy.
Heart and Trauma Research Laboratory, College of Medicine and Dentistry, James Cook University, Townsville 4811, Australia.
J Clin Med. 2021 Sep 29;10(19):4485. doi: 10.3390/jcm10194485.
Despite current advances in perioperative care, intraoperative myocardial protection during cardiac surgery has not kept the same pace. High potassium cardioplegic solutions were introduced in the 1950s, and in the early 1960s they were soon recognized as harmful. Since that time, surgeons have minimized many of the adverse effects by lowering the temperature of the heart, lowering K concentration, reducing contact K time, changing the vehicle from a crystalloid solution to whole-blood, adding many pharmacological protectants and modifying reperfusion conditions. Despite these attempts, high potassium remains a suboptimalway to arrest the heart. We briefly review the historical advances and failures of finding alternatives to high potassium, the drawbacks of a prolonged depolarized membrane, altered Ca intracellular circuits and heterogeneity in atrial-ventricular K repolarization during reanimation. Many of these untoward effects may be alleviated by a polarized membrane, and we will discuss the basic science and clinical experience from a number of institutions trialling different alternatives, and our institution with a non-depolarizing adenosine, lidocaine and magnesium (ALM) cardioplegia. The future of polarized arrest is an exciting one and may play an important role in treating the next generation of patients who are older, and sicker with multiple comorbidities and require more complex operations with prolonged cross-clamping times.
尽管目前围手术期护理取得了进展,但心脏手术中的术中心肌保护却未能同步发展。高钾心脏停搏液于20世纪50年代被引入,在20世纪60年代初很快就被认为是有害的。从那时起,外科医生通过降低心脏温度、降低钾浓度、减少钾接触时间、将载体从晶体溶液改为全血、添加多种药理保护剂以及改善再灌注条件,使许多不良反应降至最低。尽管有这些尝试,高钾仍然是一种不理想的心脏停搏方法。我们简要回顾了寻找高钾替代方法的历史进展与失败、复温过程中延长的去极化膜的缺点、改变的细胞内钙循环以及房室钾复极化的异质性。许多这些不良影响可能通过极化膜得到缓解,我们将讨论一些机构试用不同替代方法的基础科学和临床经验,以及我们机构使用非去极化的腺苷、利多卡因和镁(ALM)心脏停搏液的情况。极化停搏的未来令人兴奋,可能在治疗下一代年龄更大、病情更重、合并多种疾病且需要更复杂手术和更长交叉钳夹时间的患者中发挥重要作用。